ProKidney Corp.’s Post

How can the End Stage Renal Disease Treatment Choices (ETC) Model, the Kidney Care Choices Comprehensive Kidney Care Contracting (KCC CKCC) Model, and the new Increasing Organ Transplant Access (IOTA) Model collaboratively transform the quality of kidney care through transplantation? By leveraging metrics that incentivize kidney transplants, we can rewire local healthcare systems to improve outcomes. Barriers? Participant selection involves randomization for mandatory models (ETC & IOTA), while participation is voluntary for the KCC CKCC model. Achieving the desired outcomes of VBC arrangements is challenging when only portions of providers are aligned with similar objectives. A strategic clustered approach could dramatically overhaul a geographic network of providers, improving access to and utilization of transplantation. By creating local 'neural networks' of providers incentivized for change, this method not only drives sustainable success in value-based kidney care but also establishes transplantation as the gold standard renal replacement therapy for individuals with end-stage kidney disease. Such an alignment achieves the ultimate goal of VBC by providing high-quality care at a lower cost.

A Phase 2 #clinicaltrial has revealed that a #bonemarrowtransplant (BMT) approach, which sidesteps the use of high-dose chemotherapy, significantly enhances event-free and overall #survival rates in #patients with #sicklecell disease (#SCD). This cutting-edge method employs a non-myeloablative conditioning regimen prior to transplantation. This prepares the body to accept new cells by preserving some existing #StemCells, thereby lowering the likelihood of #donorcellrejection—a significant concern for adult recipients. Two years post-transplantation, the event-free survival rate was approximately 83%, while the overall survival rate stood at an impressive 94%, as per the reports from the #researchers. Read more 👇 https://lnkd.in/d-Yy3cBj

Explore the latest recommendations from the British Society of Haematology regarding the management of marginal zone lymphomas (#MZL). This guideline aims to offer healthcare professionals clear insights into diagnosing and managing patients with MZL. 🔬Discover the recommended diagnostic procedures, appropriate tests, and interpretation guidelines. 💡Delve into the role of radiological imaging in staging and establishing baseline measurements of the disease. 🩸Gain understanding of first-line treatment strategies tailored to various types of lymphomas and effective approaches for managing relapsed MZL. Additionally, find valuable resources on supportive care and information for patients within the guideline. Stay informed for enhanced patient care. 👉🏼https://ow.ly/FjUK50Q9pP6 #MedEd

Correlation between the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score and Left Ventricular Hypertrophy in Older Patients with Hypertension #hemoglobin #albumin #platelets #halp #leftventricularhypertrophy https://lnkd.in/gb6E6NRj

Excited to share our review on NLRP3 #inflammasome signalling in #Alzheimer’s disease with Eicke Latz. Check it out to learn the latest on NLRP3 activation, the inhibitors in #clinical trials and new NLRP3-targeted therapies under development https://lnkd.in/epPHE2gi

Safety of immunotherapy in patients with transplants remains an unanswered question. Given the life-altering consequences of a transplant, both medically and financially - a renal transplant is much less expensive than lifelong intermittent dialysis, for example - every effort should be made to preserve these precious organs. We may have gained our first inkling to the safety of immunotherapy in a very small selection of renal transplant patients. Read on to find out more in this week's Newsreel: https://lnkd.in/dUswPmzG

Efficacy of venetoclax in patients with relapsed/refractory chronic lymphocytic leukaemia: analysis of the international single-arm phase 3b trial VENICE-1

On May 17, 2024, CMS issued a proposed mandatory model, the Increasing Organ Transplant Access (IOTA) Model, which aims to increase lifesaving transplants for patients living with kidney disease and reduce medicare expenditures. Our cost-free Conversation Series Program on June 11, 2024 will provide a high-level overview of key provisions in the IOTA model, review basics of the payment policies, and outline actions transplant centers should utilize to evaluate potential impact to their own organizations. Register at no cost below.